AMENDMENTS TO THE CLAIMS

1-15. (Cancelled)

16. (Original) A method for screening a compound which is able to prevent, mitigate or treat renal glomerular lesions, lesions of pancreatic islets of Langerhans or epidermal lesions, which comprises measuring a promoting action of a compound to be tested on the induction of regeneration-promoting $CD11b^{+}CD2^{+}$ macrophages and regulatory $CD2^{-}CD4^{+}$ T lymphocytes caused by contact of human peripheral blood mononuclear cells with a lipopolysaccharide.

17. (Original) A method for screening a compound which is able to prevent, mitigate or treat renal tubulointerstitial lesions, lesions of pancreatic exocrine or interstitial tissues, or dermal lesions, which comprises measuring a promoting action of a compound to be tested on the induction of regeneration-promoting $CD11b^{-}CD2^{+}$ macrophages and/or regulatory $CD2^{-}CD4^{+}$ T lymphocytes caused by contact of human peripheral blood mononuclear cells with mitomycin-treated human peripheral blood mononuclear cells.

18-20. (Cancelled)

21. (Original) A method for suppression and/or regeneration of sclerotic lesions causing apoptosis, degeneration, fibrosis and atrophy, which comprises administering a compound which preferentially increases regeneration-promoting macrophages to a patient.

22. (Original) A therapeutic method for renal glomerular lesions, lesions of pancreatic islets of Langerhans or epidermal lesions, which comprises administering a pharmaceutical comprising a compound which promotes induction of regeneration-promoting $CD11b^{+}CD2^{+}$ macrophages to a patient.

23. (Original) The therapeutic method as claimed in claim 22, wherein the compound which preferentially increases regeneration-promoting $CD11b^+CD2^+$ macrophages is one or more compound(s) selected from the group consisting of (R)-1-naphthalen-2-ylethyl (R)-2-(4-fluorophenoxy)-5- oxotetrahydrofuran-2-carboxylate, 2-fluoro-5-oxotetrahydrofuran-2-carboxylic acid benzyl ester, bacitracin A, viomycin, 6,7-dimethoxy-1-morpholinomethyl-isochromane, 1-diethylaminomethyl-5-butoxy-6-methoxy-1,2,3,4-tetrahydroisoquinoline, 1-(4-fluorophenylthio)-2-methylaminopropanone, 2-chloro-5-oxotetrahydrofuran-2-carboxylic acid benzyl ester and 1-(2-oxo-hemiglutaric acid) benzyl ester.

24. (Original) A therapeutic method for renal tubulointerstitial lesions, lesions of pancreatic exocrine or interstitial tissues, or dermal lesions, which comprises administering a pharmaceutical comprising a compound which promotes induction of regeneration-promoting $CD11b^-CD2^+$ macrophages to a patient.

25. (Original) The therapeutic method as claimed in claim 24, wherein the compound promoting induction of regeneration-promoting $CD11b^-CD2^+$ macrophages is one or more compound(s) selected from the group consisting of (R)-1-naphthalen-2-ylethyl (S)-2-(4-fluorophenoxy)-5-oxotetrahydrofuran-2-carboxylate, 2-benzl-5-oxo-2-tetrahydrofurancarboxylic acid benzyl ester, 1-chloro-3-oxo-1,3-dihydroisobenzofuran-1-carboxylic acid benzyl ester and 1-(2-oxo-hemiglutaric acid) ethyl ester.

26. (Currently amended) A therapeutic method for kidney diseases, pancreatic diseases or skin diseases, which comprises concurrently administering ~~the pharmaceutical described in claim 22 and the pharmaceutical described in claim 24~~ a compound which promotes induction of regeneration-promoting $CD11b^+CD2^+$ macrophages and a compound which promotes induction of regeneration-promoting $CD11b^-CD2^+$ macrophages to a patient.

27. (Original) A therapeutic method for kidney diseases, pancreatic diseases or skin diseases, which comprises administering a compound which promotes induction of regeneration-promoting $CD11b^{+}CD2^{+}$ macrophages and regeneration-promoting $CD11b^{-}CD2^{+}$ macrophages to a patient.

28. (Original) The therapeutic method as claimed in claim 27, which comprises concurrently administering a compound promoting induction of regeneration-promoting $CD11b^{+}CD2^{+}$ macrophages and a compound promoting induction of regeneration-promoting $CD11b^{-}CD2^{+}$ macrophages, each of which being one or more compound(s) selected from the group consisting of
2-(4-chlorophenyl)thio-5-oxo-2-tetrahydrofuran carboxylic acid benzyl ester,
2-(4-fluorophenyl)oxy-5-oxo-2-tetrahydrofurancarboxylic acid ethyl ester,
2-(2,4-difluorophenyl)sulfonyl-5-oxo-2-tetrahydrofurancarboxylic acid benzyl ester,
2-phenoxy-5-oxo-2-tetrahydrofurancarboxylic acid benzhydryl ester,
2-(4-fluorophenyl)thio-5-oxo-2-tetrahydrofurancarboxylic acid,
2-(4-methoxyphenyl)thio-5-oxo-2-tetrahydrofurancarboxylic acid,
2-(2,4-difluorophenyl)thio-5-oxo-2-tetrahydrofurancarboxylic acid and 2-(4-fluorophenyl)sulfonyl-5-oxo-2-tetrahydrofurancarboxylic acid benzyl ester, to a patient.

29-38. (Cancelled)